Bcl-2, bax and bcl-xL expression in human sensitive and resistant leukemia cell lines

With the growing understanding of cytostatic drug-induced programmed cell death new drug-resistance mechanisms based on the altered ability of cells to die by apoptosis have been defined. At first, the sensitive and P-glycoprotein (P-gp)-related resistant cell lines were tested to induce apoptosis b...

Ausführliche Beschreibung

Gespeichert in:
Bibliographische Detailangaben
Veröffentlicht in:Leukemia 1999-11, Vol.13 (11), p.1864-1872
Hauptverfasser: Nuessler, V, Stötzer, O, Gullis, E, Pelka-Fleischer, R, Pogrebniak, A, Gieseler, F, Wilmanns, W
Format: Artikel
Sprache:eng
Schlagworte:
Online-Zugang:Volltext
Tags: Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
container_end_page 1872
container_issue 11
container_start_page 1864
container_title Leukemia
container_volume 13
creator Nuessler, V
Stötzer, O
Gullis, E
Pelka-Fleischer, R
Pogrebniak, A
Gieseler, F
Wilmanns, W
description With the growing understanding of cytostatic drug-induced programmed cell death new drug-resistance mechanisms based on the altered ability of cells to die by apoptosis have been defined. At first, the sensitive and P-glycoprotein (P-gp)-related resistant cell lines were tested to induce apoptosis by a non-P-gp transported drug, such as cytosine arabinoside (ara-C). It was demonstrated that ara-C induces apoptosis in sensitive as well as in P-gp-related resistant cell lines, as expected. Furthermore, the role of bcl-2 and bcl-xL apoptosis inhibitors as well as bax expression (apoptosis inducer) in human sensitive leukemic cell lines (CCRF-CEM and HL-60) as compared to their resistant variants such as CCRF-CEM/ACT400, CCRF-CEM/VCR1000, HL-60/IDA40, HL-60/DNR250 was evaluated. In addition to the P-gp-related resistance, a possible multidrug resistance-associated protein (MRP) and the lung resistance protein (LRP)-related resistance were assessed by flow cytometry using the monoclonal antibodies 4E3.16, MRPr1 and LRP56. Furthermore, the function of P-gp was determined with the rhodamine-123 (R-123) accumulation test. Bcl-2 and bax were analyzed by both flow cytometry and ECL Western blot, bcl-xL by ECL-Western blot alone. Comparison of the two sensitive cell lines demonstrated different bcl-2, bax and bcl-xL patterns. The common characteristic was the increased expression of one of the apoptosis inhibitor proteins, such as bcl-2 or bcl-xL. The sensitive CCRF-CEM showed a high bax level, where a decrease of about 75% in resistant variants was measured. Compared to their sensitive counterpart HL-60, a low bax expression was analyzed, which increased in the resistant variant. The common characteristic of all resistant cell lines was the decreased expression of bax compared to bcl-2 or bcl-xL. In the P-gp-related resistant HL-60/DNR250 only an increase in bcl-xL was seen, whereas in the LRP-expressing as well as P-gp and MRP negative resistant HL-60/IDA40 both apoptotic inhibitor proteins bcl-2 and bcL-xL showed maximum increase, compared to the other resistant cell lines. The P-gp-related resistant cell lines CCRF-CEM/ACT400 and CCRF-CEM/VCR1000 also showed an increased expression of both bcl-2 and bcl-xL. Summarizing these results, it was shown that the examined sensitive human leukemic cell lines and their resistant variants demonstrated a different pattern of markers for preventing and promoting apoptosis. An association between P-gp and possible LRP-expressi
doi_str_mv 10.1038/sj.leu.2401571
format Article
fullrecord <record><control><sourceid>proquest_pubme</sourceid><recordid>TN_cdi_proquest_miscellaneous_17436847</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><sourcerecordid>17436847</sourcerecordid><originalsourceid>FETCH-LOGICAL-j372t-b4fe427b25b7d940dbf4689b4f08d1a7762e5b2f2ea2ad6e1ebda139846f542d3</originalsourceid><addsrcrecordid>eNpdkEtPwzAQhC0EoqVw5YgsIXEixW87R6h4SZW40HNk1xvhkDglTlD596RQLpxWu_NpZrQInVMyp4Sbm1TNaxjmTBAqNT1AUyq0yqSU9BBNiTE6UzkTE3SSUkXITlTHaEKJlJooMUWru3WdsWvs7Bbb6LEb1-0Sw3bTQUqhjThE_DY0NuIEMYU-fMIPOMoh9Tb2eMx_hyZYvIa6xnWIkE7RUWnrBGf7OUOrh_vXxVO2fHl8Xtwus4pr1mdOlCCYdkw67XNBvCuFMvl4JsZTq7ViIB0rGVhmvQIKzlvKcyNUKQXzfIaufn03XfsxQOqLJqRdDRuhHVJBteDKCD2Cl__Aqh26OHYrmBJSGc0kH6mLPTW4Bnyx6UJju6_i7138G62VbBs</addsrcrecordid><sourcetype>Aggregation Database</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>2645687253</pqid></control><display><type>article</type><title>Bcl-2, bax and bcl-xL expression in human sensitive and resistant leukemia cell lines</title><source>MEDLINE</source><source>Nature</source><source>EZB-FREE-00999 freely available EZB journals</source><source>Alma/SFX Local Collection</source><creator>Nuessler, V ; Stötzer, O ; Gullis, E ; Pelka-Fleischer, R ; Pogrebniak, A ; Gieseler, F ; Wilmanns, W</creator><creatorcontrib>Nuessler, V ; Stötzer, O ; Gullis, E ; Pelka-Fleischer, R ; Pogrebniak, A ; Gieseler, F ; Wilmanns, W</creatorcontrib><description>With the growing understanding of cytostatic drug-induced programmed cell death new drug-resistance mechanisms based on the altered ability of cells to die by apoptosis have been defined. At first, the sensitive and P-glycoprotein (P-gp)-related resistant cell lines were tested to induce apoptosis by a non-P-gp transported drug, such as cytosine arabinoside (ara-C). It was demonstrated that ara-C induces apoptosis in sensitive as well as in P-gp-related resistant cell lines, as expected. Furthermore, the role of bcl-2 and bcl-xL apoptosis inhibitors as well as bax expression (apoptosis inducer) in human sensitive leukemic cell lines (CCRF-CEM and HL-60) as compared to their resistant variants such as CCRF-CEM/ACT400, CCRF-CEM/VCR1000, HL-60/IDA40, HL-60/DNR250 was evaluated. In addition to the P-gp-related resistance, a possible multidrug resistance-associated protein (MRP) and the lung resistance protein (LRP)-related resistance were assessed by flow cytometry using the monoclonal antibodies 4E3.16, MRPr1 and LRP56. Furthermore, the function of P-gp was determined with the rhodamine-123 (R-123) accumulation test. Bcl-2 and bax were analyzed by both flow cytometry and ECL Western blot, bcl-xL by ECL-Western blot alone. Comparison of the two sensitive cell lines demonstrated different bcl-2, bax and bcl-xL patterns. The common characteristic was the increased expression of one of the apoptosis inhibitor proteins, such as bcl-2 or bcl-xL. The sensitive CCRF-CEM showed a high bax level, where a decrease of about 75% in resistant variants was measured. Compared to their sensitive counterpart HL-60, a low bax expression was analyzed, which increased in the resistant variant. The common characteristic of all resistant cell lines was the decreased expression of bax compared to bcl-2 or bcl-xL. In the P-gp-related resistant HL-60/DNR250 only an increase in bcl-xL was seen, whereas in the LRP-expressing as well as P-gp and MRP negative resistant HL-60/IDA40 both apoptotic inhibitor proteins bcl-2 and bcL-xL showed maximum increase, compared to the other resistant cell lines. The P-gp-related resistant cell lines CCRF-CEM/ACT400 and CCRF-CEM/VCR1000 also showed an increased expression of both bcl-2 and bcl-xL. Summarizing these results, it was shown that the examined sensitive human leukemic cell lines and their resistant variants demonstrated a different pattern of markers for preventing and promoting apoptosis. An association between P-gp and possible LRP-expressing leukemic cells as well as apoptosis-preventing markers (bcl-2, bcl-xL) seems to exist. The clinical relevance of the coexpression of various resistance mechanisms remains to be confirmed in large leukemia patient groups.</description><identifier>ISSN: 0887-6924</identifier><identifier>EISSN: 1476-5551</identifier><identifier>DOI: 10.1038/sj.leu.2401571</identifier><identifier>PMID: 10557064</identifier><language>eng</language><publisher>England: Nature Publishing Group</publisher><subject>Annexin A5 - analysis ; Antineoplastic Agents - pharmacology ; Apoptosis ; Apoptosis - drug effects ; ATP Binding Cassette Transporter, Sub-Family B - metabolism ; ATP-Binding Cassette Transporters - analysis ; BAX protein ; Bcl-2 protein ; bcl-2-Associated X Protein ; Bcl-x protein ; Blotting, Western ; Cell death ; Cytarabine ; Cytarabine - pharmacology ; Cytosine ; Drug Resistance, Neoplasm ; Drug Screening Assays, Antitumor ; Flow Cytometry ; Gene Expression ; glycoprotein P ; Glycoproteins ; HL-60 Cells ; Humans ; Inhibitors ; Inhibitory Concentration 50 ; Leukemia ; Leukemia - metabolism ; Leukemia - pathology ; Markers ; Material requirements planning ; Microscopy, Fluorescence ; Monoclonal antibodies ; Multidrug resistance ; Multidrug Resistance-Associated Proteins ; Multidrug resistant organisms ; Neoplasm Proteins ; P-Glycoprotein ; Proteins ; Proto-Oncogene Proteins - biosynthesis ; Proto-Oncogene Proteins c-bcl-2 - biosynthesis ; Rhodamine ; Tumor cell lines ; Tumor Cells, Cultured ; Vault Ribonucleoprotein Particles</subject><ispartof>Leukemia, 1999-11, Vol.13 (11), p.1864-1872</ispartof><rights>Macmillan Publishers Limited 1999.</rights><lds50>peer_reviewed</lds50><oa>free_for_read</oa><woscitedreferencessubscribed>false</woscitedreferencessubscribed></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><link.rule.ids>314,780,784,27924,27925</link.rule.ids><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/10557064$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><creatorcontrib>Nuessler, V</creatorcontrib><creatorcontrib>Stötzer, O</creatorcontrib><creatorcontrib>Gullis, E</creatorcontrib><creatorcontrib>Pelka-Fleischer, R</creatorcontrib><creatorcontrib>Pogrebniak, A</creatorcontrib><creatorcontrib>Gieseler, F</creatorcontrib><creatorcontrib>Wilmanns, W</creatorcontrib><title>Bcl-2, bax and bcl-xL expression in human sensitive and resistant leukemia cell lines</title><title>Leukemia</title><addtitle>Leukemia</addtitle><description>With the growing understanding of cytostatic drug-induced programmed cell death new drug-resistance mechanisms based on the altered ability of cells to die by apoptosis have been defined. At first, the sensitive and P-glycoprotein (P-gp)-related resistant cell lines were tested to induce apoptosis by a non-P-gp transported drug, such as cytosine arabinoside (ara-C). It was demonstrated that ara-C induces apoptosis in sensitive as well as in P-gp-related resistant cell lines, as expected. Furthermore, the role of bcl-2 and bcl-xL apoptosis inhibitors as well as bax expression (apoptosis inducer) in human sensitive leukemic cell lines (CCRF-CEM and HL-60) as compared to their resistant variants such as CCRF-CEM/ACT400, CCRF-CEM/VCR1000, HL-60/IDA40, HL-60/DNR250 was evaluated. In addition to the P-gp-related resistance, a possible multidrug resistance-associated protein (MRP) and the lung resistance protein (LRP)-related resistance were assessed by flow cytometry using the monoclonal antibodies 4E3.16, MRPr1 and LRP56. Furthermore, the function of P-gp was determined with the rhodamine-123 (R-123) accumulation test. Bcl-2 and bax were analyzed by both flow cytometry and ECL Western blot, bcl-xL by ECL-Western blot alone. Comparison of the two sensitive cell lines demonstrated different bcl-2, bax and bcl-xL patterns. The common characteristic was the increased expression of one of the apoptosis inhibitor proteins, such as bcl-2 or bcl-xL. The sensitive CCRF-CEM showed a high bax level, where a decrease of about 75% in resistant variants was measured. Compared to their sensitive counterpart HL-60, a low bax expression was analyzed, which increased in the resistant variant. The common characteristic of all resistant cell lines was the decreased expression of bax compared to bcl-2 or bcl-xL. In the P-gp-related resistant HL-60/DNR250 only an increase in bcl-xL was seen, whereas in the LRP-expressing as well as P-gp and MRP negative resistant HL-60/IDA40 both apoptotic inhibitor proteins bcl-2 and bcL-xL showed maximum increase, compared to the other resistant cell lines. The P-gp-related resistant cell lines CCRF-CEM/ACT400 and CCRF-CEM/VCR1000 also showed an increased expression of both bcl-2 and bcl-xL. Summarizing these results, it was shown that the examined sensitive human leukemic cell lines and their resistant variants demonstrated a different pattern of markers for preventing and promoting apoptosis. An association between P-gp and possible LRP-expressing leukemic cells as well as apoptosis-preventing markers (bcl-2, bcl-xL) seems to exist. The clinical relevance of the coexpression of various resistance mechanisms remains to be confirmed in large leukemia patient groups.</description><subject>Annexin A5 - analysis</subject><subject>Antineoplastic Agents - pharmacology</subject><subject>Apoptosis</subject><subject>Apoptosis - drug effects</subject><subject>ATP Binding Cassette Transporter, Sub-Family B - metabolism</subject><subject>ATP-Binding Cassette Transporters - analysis</subject><subject>BAX protein</subject><subject>Bcl-2 protein</subject><subject>bcl-2-Associated X Protein</subject><subject>Bcl-x protein</subject><subject>Blotting, Western</subject><subject>Cell death</subject><subject>Cytarabine</subject><subject>Cytarabine - pharmacology</subject><subject>Cytosine</subject><subject>Drug Resistance, Neoplasm</subject><subject>Drug Screening Assays, Antitumor</subject><subject>Flow Cytometry</subject><subject>Gene Expression</subject><subject>glycoprotein P</subject><subject>Glycoproteins</subject><subject>HL-60 Cells</subject><subject>Humans</subject><subject>Inhibitors</subject><subject>Inhibitory Concentration 50</subject><subject>Leukemia</subject><subject>Leukemia - metabolism</subject><subject>Leukemia - pathology</subject><subject>Markers</subject><subject>Material requirements planning</subject><subject>Microscopy, Fluorescence</subject><subject>Monoclonal antibodies</subject><subject>Multidrug resistance</subject><subject>Multidrug Resistance-Associated Proteins</subject><subject>Multidrug resistant organisms</subject><subject>Neoplasm Proteins</subject><subject>P-Glycoprotein</subject><subject>Proteins</subject><subject>Proto-Oncogene Proteins - biosynthesis</subject><subject>Proto-Oncogene Proteins c-bcl-2 - biosynthesis</subject><subject>Rhodamine</subject><subject>Tumor cell lines</subject><subject>Tumor Cells, Cultured</subject><subject>Vault Ribonucleoprotein Particles</subject><issn>0887-6924</issn><issn>1476-5551</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>1999</creationdate><recordtype>article</recordtype><sourceid>EIF</sourceid><recordid>eNpdkEtPwzAQhC0EoqVw5YgsIXEixW87R6h4SZW40HNk1xvhkDglTlD596RQLpxWu_NpZrQInVMyp4Sbm1TNaxjmTBAqNT1AUyq0yqSU9BBNiTE6UzkTE3SSUkXITlTHaEKJlJooMUWru3WdsWvs7Bbb6LEb1-0Sw3bTQUqhjThE_DY0NuIEMYU-fMIPOMoh9Tb2eMx_hyZYvIa6xnWIkE7RUWnrBGf7OUOrh_vXxVO2fHl8Xtwus4pr1mdOlCCYdkw67XNBvCuFMvl4JsZTq7ViIB0rGVhmvQIKzlvKcyNUKQXzfIaufn03XfsxQOqLJqRdDRuhHVJBteDKCD2Cl__Aqh26OHYrmBJSGc0kH6mLPTW4Bnyx6UJju6_i7138G62VbBs</recordid><startdate>19991101</startdate><enddate>19991101</enddate><creator>Nuessler, V</creator><creator>Stötzer, O</creator><creator>Gullis, E</creator><creator>Pelka-Fleischer, R</creator><creator>Pogrebniak, A</creator><creator>Gieseler, F</creator><creator>Wilmanns, W</creator><general>Nature Publishing Group</general><scope>CGR</scope><scope>CUY</scope><scope>CVF</scope><scope>ECM</scope><scope>EIF</scope><scope>NPM</scope><scope>7QL</scope><scope>7T5</scope><scope>7T7</scope><scope>7TM</scope><scope>7TO</scope><scope>7U9</scope><scope>8FD</scope><scope>C1K</scope><scope>FR3</scope><scope>H94</scope><scope>K9.</scope><scope>M7N</scope><scope>NAPCQ</scope><scope>P64</scope></search><sort><creationdate>19991101</creationdate><title>Bcl-2, bax and bcl-xL expression in human sensitive and resistant leukemia cell lines</title><author>Nuessler, V ; Stötzer, O ; Gullis, E ; Pelka-Fleischer, R ; Pogrebniak, A ; Gieseler, F ; Wilmanns, W</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-j372t-b4fe427b25b7d940dbf4689b4f08d1a7762e5b2f2ea2ad6e1ebda139846f542d3</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>1999</creationdate><topic>Annexin A5 - analysis</topic><topic>Antineoplastic Agents - pharmacology</topic><topic>Apoptosis</topic><topic>Apoptosis - drug effects</topic><topic>ATP Binding Cassette Transporter, Sub-Family B - metabolism</topic><topic>ATP-Binding Cassette Transporters - analysis</topic><topic>BAX protein</topic><topic>Bcl-2 protein</topic><topic>bcl-2-Associated X Protein</topic><topic>Bcl-x protein</topic><topic>Blotting, Western</topic><topic>Cell death</topic><topic>Cytarabine</topic><topic>Cytarabine - pharmacology</topic><topic>Cytosine</topic><topic>Drug Resistance, Neoplasm</topic><topic>Drug Screening Assays, Antitumor</topic><topic>Flow Cytometry</topic><topic>Gene Expression</topic><topic>glycoprotein P</topic><topic>Glycoproteins</topic><topic>HL-60 Cells</topic><topic>Humans</topic><topic>Inhibitors</topic><topic>Inhibitory Concentration 50</topic><topic>Leukemia</topic><topic>Leukemia - metabolism</topic><topic>Leukemia - pathology</topic><topic>Markers</topic><topic>Material requirements planning</topic><topic>Microscopy, Fluorescence</topic><topic>Monoclonal antibodies</topic><topic>Multidrug resistance</topic><topic>Multidrug Resistance-Associated Proteins</topic><topic>Multidrug resistant organisms</topic><topic>Neoplasm Proteins</topic><topic>P-Glycoprotein</topic><topic>Proteins</topic><topic>Proto-Oncogene Proteins - biosynthesis</topic><topic>Proto-Oncogene Proteins c-bcl-2 - biosynthesis</topic><topic>Rhodamine</topic><topic>Tumor cell lines</topic><topic>Tumor Cells, Cultured</topic><topic>Vault Ribonucleoprotein Particles</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Nuessler, V</creatorcontrib><creatorcontrib>Stötzer, O</creatorcontrib><creatorcontrib>Gullis, E</creatorcontrib><creatorcontrib>Pelka-Fleischer, R</creatorcontrib><creatorcontrib>Pogrebniak, A</creatorcontrib><creatorcontrib>Gieseler, F</creatorcontrib><creatorcontrib>Wilmanns, W</creatorcontrib><collection>Medline</collection><collection>MEDLINE</collection><collection>MEDLINE (Ovid)</collection><collection>MEDLINE</collection><collection>MEDLINE</collection><collection>PubMed</collection><collection>Bacteriology Abstracts (Microbiology B)</collection><collection>Immunology Abstracts</collection><collection>Industrial and Applied Microbiology Abstracts (Microbiology A)</collection><collection>Nucleic Acids Abstracts</collection><collection>Oncogenes and Growth Factors Abstracts</collection><collection>Virology and AIDS Abstracts</collection><collection>Technology Research Database</collection><collection>Environmental Sciences and Pollution Management</collection><collection>Engineering Research Database</collection><collection>AIDS and Cancer Research Abstracts</collection><collection>ProQuest Health &amp; Medical Complete (Alumni)</collection><collection>Algology Mycology and Protozoology Abstracts (Microbiology C)</collection><collection>Nursing &amp; Allied Health Premium</collection><collection>Biotechnology and BioEngineering Abstracts</collection><jtitle>Leukemia</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Nuessler, V</au><au>Stötzer, O</au><au>Gullis, E</au><au>Pelka-Fleischer, R</au><au>Pogrebniak, A</au><au>Gieseler, F</au><au>Wilmanns, W</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>Bcl-2, bax and bcl-xL expression in human sensitive and resistant leukemia cell lines</atitle><jtitle>Leukemia</jtitle><addtitle>Leukemia</addtitle><date>1999-11-01</date><risdate>1999</risdate><volume>13</volume><issue>11</issue><spage>1864</spage><epage>1872</epage><pages>1864-1872</pages><issn>0887-6924</issn><eissn>1476-5551</eissn><abstract>With the growing understanding of cytostatic drug-induced programmed cell death new drug-resistance mechanisms based on the altered ability of cells to die by apoptosis have been defined. At first, the sensitive and P-glycoprotein (P-gp)-related resistant cell lines were tested to induce apoptosis by a non-P-gp transported drug, such as cytosine arabinoside (ara-C). It was demonstrated that ara-C induces apoptosis in sensitive as well as in P-gp-related resistant cell lines, as expected. Furthermore, the role of bcl-2 and bcl-xL apoptosis inhibitors as well as bax expression (apoptosis inducer) in human sensitive leukemic cell lines (CCRF-CEM and HL-60) as compared to their resistant variants such as CCRF-CEM/ACT400, CCRF-CEM/VCR1000, HL-60/IDA40, HL-60/DNR250 was evaluated. In addition to the P-gp-related resistance, a possible multidrug resistance-associated protein (MRP) and the lung resistance protein (LRP)-related resistance were assessed by flow cytometry using the monoclonal antibodies 4E3.16, MRPr1 and LRP56. Furthermore, the function of P-gp was determined with the rhodamine-123 (R-123) accumulation test. Bcl-2 and bax were analyzed by both flow cytometry and ECL Western blot, bcl-xL by ECL-Western blot alone. Comparison of the two sensitive cell lines demonstrated different bcl-2, bax and bcl-xL patterns. The common characteristic was the increased expression of one of the apoptosis inhibitor proteins, such as bcl-2 or bcl-xL. The sensitive CCRF-CEM showed a high bax level, where a decrease of about 75% in resistant variants was measured. Compared to their sensitive counterpart HL-60, a low bax expression was analyzed, which increased in the resistant variant. The common characteristic of all resistant cell lines was the decreased expression of bax compared to bcl-2 or bcl-xL. In the P-gp-related resistant HL-60/DNR250 only an increase in bcl-xL was seen, whereas in the LRP-expressing as well as P-gp and MRP negative resistant HL-60/IDA40 both apoptotic inhibitor proteins bcl-2 and bcL-xL showed maximum increase, compared to the other resistant cell lines. The P-gp-related resistant cell lines CCRF-CEM/ACT400 and CCRF-CEM/VCR1000 also showed an increased expression of both bcl-2 and bcl-xL. Summarizing these results, it was shown that the examined sensitive human leukemic cell lines and their resistant variants demonstrated a different pattern of markers for preventing and promoting apoptosis. An association between P-gp and possible LRP-expressing leukemic cells as well as apoptosis-preventing markers (bcl-2, bcl-xL) seems to exist. The clinical relevance of the coexpression of various resistance mechanisms remains to be confirmed in large leukemia patient groups.</abstract><cop>England</cop><pub>Nature Publishing Group</pub><pmid>10557064</pmid><doi>10.1038/sj.leu.2401571</doi><tpages>9</tpages><oa>free_for_read</oa></addata></record>
fulltext fulltext
identifier ISSN: 0887-6924
ispartof Leukemia, 1999-11, Vol.13 (11), p.1864-1872
issn 0887-6924
1476-5551
language eng
recordid cdi_proquest_miscellaneous_17436847
source MEDLINE; Nature; EZB-FREE-00999 freely available EZB journals; Alma/SFX Local Collection
subjects Annexin A5 - analysis
Antineoplastic Agents - pharmacology
Apoptosis
Apoptosis - drug effects
ATP Binding Cassette Transporter, Sub-Family B - metabolism
ATP-Binding Cassette Transporters - analysis
BAX protein
Bcl-2 protein
bcl-2-Associated X Protein
Bcl-x protein
Blotting, Western
Cell death
Cytarabine
Cytarabine - pharmacology
Cytosine
Drug Resistance, Neoplasm
Drug Screening Assays, Antitumor
Flow Cytometry
Gene Expression
glycoprotein P
Glycoproteins
HL-60 Cells
Humans
Inhibitors
Inhibitory Concentration 50
Leukemia
Leukemia - metabolism
Leukemia - pathology
Markers
Material requirements planning
Microscopy, Fluorescence
Monoclonal antibodies
Multidrug resistance
Multidrug Resistance-Associated Proteins
Multidrug resistant organisms
Neoplasm Proteins
P-Glycoprotein
Proteins
Proto-Oncogene Proteins - biosynthesis
Proto-Oncogene Proteins c-bcl-2 - biosynthesis
Rhodamine
Tumor cell lines
Tumor Cells, Cultured
Vault Ribonucleoprotein Particles
title Bcl-2, bax and bcl-xL expression in human sensitive and resistant leukemia cell lines
url https://sfx.bib-bvb.de/sfx_tum?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2024-12-26T11%3A37%3A02IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-proquest_pubme&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=Bcl-2,%20bax%20and%20bcl-xL%20expression%20in%20human%20sensitive%20and%20resistant%20leukemia%20cell%20lines&rft.jtitle=Leukemia&rft.au=Nuessler,%20V&rft.date=1999-11-01&rft.volume=13&rft.issue=11&rft.spage=1864&rft.epage=1872&rft.pages=1864-1872&rft.issn=0887-6924&rft.eissn=1476-5551&rft_id=info:doi/10.1038/sj.leu.2401571&rft_dat=%3Cproquest_pubme%3E17436847%3C/proquest_pubme%3E%3Curl%3E%3C/url%3E&disable_directlink=true&sfx.directlink=off&sfx.report_link=0&rft_id=info:oai/&rft_pqid=2645687253&rft_id=info:pmid/10557064&rfr_iscdi=true